[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"papillary-thyroid-microcarcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:papillary-thyroid-microcarcinoma":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,40,67,99,121,148],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100453844","rfa-treatment-for-papillary-thyroid-microcarcinoma-100453844",false,"NCT05189821","RFA Treatment for Papillary Thyroid Microcarcinoma","RFA Treatment for Papillary Thyroid Microcarcinoma Cohort","Inclusion Criteria:\n\n* Adult patients (\\>\u002F= 18 years)\n* Biopsy proven papillary thyroid microcarcinoma (\\>\u002F= 1.5cm in greatest diameter, PTMC)\n* Either refuse surgery or are not good surgical candidates\n\nExclusion Criteria:\n\n* Cardiac arrhythmia\n* Pregnancy","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","OBSERVATIONAL","Thyroid surgery has always been the mainstay of treatment for thyroid cancer. Thyroid surgery carries a low risk of complications that include recurrent or superior laryngeal nerve injury leading to voice changes, hypoparathyroidism, hypothyroidism with need for thyroid hormone supplementation, and unsightly scarring. Although many patients with thyroid cancer find these risks acceptable, these risks are sometimes less acceptable to patients with benign disease. In an era when the medical field is treating thyroid diseases less aggressively, there is a pressing need to identify approaches to treat indolent malignant disease less invasively.\n\nThe purpose of this observational study is to evaluate the efficacy and safety of Radiofrequency Ablation (RFA) for treatment of Papillary Thyroid Microcarcinoma (PTMC) in patients that have already agreed to RFA procedure based on treating physician recommendation. This is a data collection study in which we ask participants to give us access to information generated before and after RFA treatment of their condition. The RFA procedure uses image guidance to place an electrode through the skin into the target tumor. In RFA, high-frequency electrical currents are passed through an electrode, creating a small region of heat to treat the lesion.",[24],"Papillary Thyroid Microcarcinoma",[26],"Radiofrequency Ablation","RECRUITING","2026-05-27",{"date":30,"type":31},"2026-05-29","ACTUAL",{"date":33,"type":31},"2021-11-01",{"date":35,"type":20},"2028-11",{"name":37,"class":38},"Columbia University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":39},"100255866","active-surveillance-of-papillary-thyroid-microcarcinoma-100255866","NCT02609685","Active Surveillance of Papillary Thyroid Microcarcinoma","PMCAS","Inclusion Criteria:\n\n* Pathologically confirmed Bethesda V or VI thyroid nodules with papillary thyroid carcinoma or high clinical suspicion, or pathologically confirmed Bethesda III or IV nodules with BRAF mutation.\n* 2.0 cm or smaller nodules by ultrasonographic criteria\n* Ability to understand and the willingness to sign a written informed consent and HIPAA Authorization form\n* Must be able to read and write English fluently to participate in the questionnaire portion of the study\n\nExclusion Criteria:\n\n* High-grade or poorly differentiated PTC variants\n* Central or lateral neck lymphadenopathy suspicious for PTC\n* Unfavorable nodule location (e.g. Near dorsal surface (by recurrent laryngeal nerve); Adjacent to trachea (risk of cartilage invasion)\n* History of radiation to neck",{"count":48,"type":20},216,"INTERVENTIONAL",[51],"NA","The purpose of this study is to better understand the outcomes of active surveillance (observation) instead of immediate surgery, which is the current standard of care for papillary thyroid microcarcinoma (PTMC). Patients with a 1.5 cm or smaller thyroid nodule(s) with papillary thyroid carcinoma will be eligible for the study.",[24],[55,56,57],"Thyroid cancer","Active surveillance","PTMC","2026-05-01",{"date":60,"type":31},"2026-05-07",{"date":62,"type":31},"2016-05-13",{"date":64,"type":20},"2030-12",{"name":66,"class":38},"Cedars-Sinai Medical Center",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":49,"phases":76,"briefSummary":77,"conditions":78,"keywords":81,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":39},"100634186","decision-aid-efficacy-in-low-risk-thyroid-cancer-100634186","NCT07536412","Decision Aid Efficacy in Low Risk Thyroid Cancer","Efficacy of a Patient-facing Decision Aid in Reducing Decision Anxiety and Improving Decision Readiness in Low Risk Thyroid Cancer","Inclusion Criteria:\n\n* Low-risk thyroid cancer or thyroid nodule suspicious for malignancy\n* English-speaking\n\nExclusion Criteria:\n\n* Prior consultation with surgeon regarding the thyroid nodule \u002F cancer in question\n* Cancer\u002Fnodule has high risk features (e.g. extrathyroidal extension on ultrasound)\n* History of thyroid cancer\n* History of thyroid surgery\n* Currently pregnant (per patient report)",{"count":75,"type":20},34,[51],"Low-risk thyroid cancer grows very slowly. More than 99% of patients with this cancer survive for at least 5 years. There are 3 main treatment options: remove the whole thyroid, remove just the part of the thyroid with the cancer in it, or leave the cancer in the thyroid and monitor it. Survival is similar across the 3 main treatment options. It can be difficult for patients to choose a treatment option, especially when feeling anxious about the cancer diagnosis. In this study, enrolled patients will receive a decision aid after finding out they have cancer but before meeting a surgeon. This decision aid is a pamphlet. It gives information about the treatment options and a list of questions for patients to ask their surgeons at their clinic visit. The investigators will test whether this aid changes patient decision anxiety and decision readiness.",[79,24,80],"Differentiated Thyroid Cancer (DTC)","Papillary Thyroid Carcinoma",[82,83,84,85,86,87,88],"decision","decision aid","thyroid cancer","papillary thyroid microcarcinoma","decision readiness","decisional conflict","overtreatment","NOT_YET_RECRUITING","2026-04-11",{"date":92,"type":31},"2026-04-17",{"date":94,"type":20},"2026-05-15",{"date":96,"type":20},"2029-06-15",{"name":98,"class":38},"University of Maryland, Baltimore",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":107,"targetDuration":109,"studyType":21,"phases":4,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":39},"100612095","safety-and-quality-of-life-of-three-treatment-strategies-for-low-risk-papillary-thyroid-microcarcinoma-100612095","NCT07249125","Safety and Quality of Life of Three Treatment Strategies for Low-Risk Papillary Thyroid Microcarcinoma","A Prospective Registry Study Evaluating the Safety and Quality of Life of Three Treatment Strategies - Surgical Resection, Thermal Ablation, and Active Surveillance - for Patients With Low-Risk Papillary Thyroid Microcarcinoma","PTMC-3S","Inclusion Criteria:\n\n* A single papillary thyroid carcinoma (PTC) lesion with a maximum diameter ≤ 1 cm confirmed by imaging.\n* No evidence of extrathyroidal extension on imaging studies.\n* No clinical or radiologic evidence of cervical lymph node metastasis.\n* No evidence of distant metastasis.\n* Histopathological confirmation of papillary thyroid carcinoma.\n* The patient has provided written informed consent and agrees to select one of the predefined management strategies (surgical resection, thermal ablation, or active surveillance).\n\nExclusion Criteria:\n\n* Ultrasound-confirmed tumor with a maximum diameter \\> 1 cm.\n* Imaging findings (ultrasound\u002FCT\u002FMRI) suggestive of extrathyroidal extension.\n* Tumor located adjacent to critical structures (e.g., trachea, esophagus, or recurrent laryngeal nerve) with possible invasion risk.\n* History of thyroidectomy, radiofrequency\u002Fmicrowave\u002Flaser ablation, or radioactive iodine therapy.\n* Failure to provide written informed consent.",{"count":108,"type":20},1630,"10 Years","This is a prospective observational patient registry study designed to evaluate the safety and quality of life associated with three treatment strategies for patients diagnosed with low-risk papillary thyroid microcarcinoma (PTMC): surgical resection, thermal ablation, and active surveillance.\n\nThe study aims to collect standardized, real-world clinical data from participating centers. Patients will receive one of the three treatment strategies according to clinical judgment and personal preference. The study team will prospectively follow participants to record safety events, disease progression, and patient-reported quality of life outcomes.\n\nBy comparing the outcomes among the three treatment groups, this registry seeks to provide evidence to support personalized and evidence-based decision-making for the management of low-risk PTMC.",[24],"2025-11-18",{"date":114,"type":31},"2025-11-25",{"date":116,"type":20},"2025-12-01",{"date":118,"type":20},"2039-06-01",{"name":120,"class":38},"Xijing Hospital",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":127,"enrollmentInfo":128,"targetDuration":130,"studyType":21,"phases":4,"briefSummary":131,"conditions":132,"keywords":136,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":39},"100597110","efficacy-and-prognosis-of-microwave-ablation-treatment-for-papillary-thyroid-microcarcinoma-assessed-by-contrast-enhanced-ultrasound-combined-with-genetic-and-molecular-diagnostics-a-prospective-observational-study-100597110","NCT07054229","Efficacy and Prognosis of Microwave Ablation Treatment for Papillary Thyroid Microcarcinoma Assessed by Contrast-Enhanced Ultrasound Combined With Genetic and Molecular Diagnostics: A Prospective Observational Study","Inclusion Criteria:\n\n* Aged 18-70 years, gender not specified;\n* Patients with low-risk PTMC receiving initial treatment (meeting all the following conditions: single lesion with a maximum diameter ≤1cm; no cervical lymph node metastasis; no distant metastasis; no extrathyroidal extension; no family history of thyroid cancer; no history of head and neck radiation during childhood);\n* Patients who have undergone fine-needle aspiration cytology examination of thyroid nodules and 88-gene panel testing for thyroid cancer before surgery;\n* Patients voluntarily choose to undergo microwave ablation therapy or surgical resection.\n\nExclusion Criteria:\n\n* Tumor located in the isthmus of the thyroid;\n* Pathological high-risk subtypes (tall cell subtype, columnar cell subtype, diffuse sclerosing subtype, solid\u002Finsular subtype, oncocytic subtype);\n* Progressive enlargement of the cancer lesion in the short term (increase of more than 3mm within 6 months);\n* Pregnant women, lactating women;\n* Patients with severe coagulation disorders;\n* Patients with contralateral vocal cord dysfunction;\n* Patients with contraindications to ultrasound contrast agents;\n* Other conditions deemed ineligible for enrollment by the investigator.","70 Years",{"count":129,"type":20},480,"6 Months","In 2016, there were 203,000 new cases of thyroid cancer in China, ranking 7th among all malignant tumours and 4th among women, and showing a rapid growth trend. Papillary thyroid cancer (PTMC) with a diameter of ≤10 mm is the most common type of thyroid cancer, accounting for about 50% to 60% of the total number of cases. Low-risk PTMC is the most common type of thyroid cancer, with low invasiveness and good prognosis. Surgery is the treatment of choice for low-risk PTMC, but it significantly affects the quality of life of patients by affecting the function of the thyroid gland and requiring long-term medication after surgery, as well as having a high incidence of intra- and postoperative complications; there are certain impacts and limitations in the actual treatment. Microwave ablation (MWA) is a therapeutic modality emerging in recent years, which has the characteristics of easy operation, precise positioning, safety and effectiveness, small postoperative damage, fast recovery, fewer complications, and does not affect the aesthetics of the patient, which not only avoids surgical trauma and reduces the anxiety of the patient, but also better preserves the function of the thyroid gland, and its clinical application is becoming more and more widespread. In recent years, the application of microwave ablation in the treatment of PTMC has received more and more attention. Ultrasound, as a first-line examination tool, is accepted by the majority of patients because of its advantages of safety, speed, efficiency, low price and painlessness. Contrast-enhanced ultrasound (CEUS) is a new examination technique developed in recent years, which can provide richer and clearer diagnostic information than conventional ultrasound and colour Doppler ultrasound. Ultrasound contrast agents (e.g. Sonovue, Sonazoid), Sonovue with sulphur hexafluoride microbubbles as the main ingredient and Sonazoid with perfluorobutane microbubbles as the main ingredient, are non-toxic, non-radioactive, do not require allergy testing, and do not have the advantages of liver or kidney toxicity, etc., and are increasingly recognised by the public. Ultrasonography is now widely used in clinical practice as the primary modality for assessing efficacy after thyroid ablation therapy. Molecular diagnosis is one of the most important tools for preoperative diagnosis and invasiveness assessment of thyroid cancer. Common thyroid cancer gene variants include point mutations such as BRAF V600E, RAS, TP53, PIK3CA, and gene integration variants such as CCDC6-RET and ETV6-NTRK3. This project intends to assess the efficacy and prognosis of microwave ablation therapy for micropapillary thyroid cancer by ultrasonography combined with genetic molecular diagnosis, which in turn will assist in clinical treatment decisions.",[133,134,135,24],"Microwave Ablation","Contrast-enhanced Ultrasound","Genetic and Molecular Diagnostics",[137,24,138,135],"microwave ablation","contrast-enhanced ultrasound","2025-06-26",{"date":141,"type":31},"2025-07-08",{"date":143,"type":31},"2024-01-01",{"date":145,"type":20},"2026-12-31",{"name":147,"class":38},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":39},"100541724","minimally-invasive-treatments-of-the-thyroid-100541724","NCT06333587","Minimally Invasive Treatments of the Thyroid","Multicenter International Prospective Analysis on Minimally Invasive Treatments of the Thyroid (MIPA- MITT) of of Micropapillary Thyroid Carcinoma","MIPA-MITT","Inclusion Criteria:\n\n* Patients \\> 18years\n* Patients with diagnosis of papillary thyroid microcarcinoma, citologically proven, suitable for MITT.\n* Written informed consent must be signed and dated by the patient and the investigator prior to inclusion.\n* Patients must be accessible for follow-up\n\nExclusion Criteria:\n\n* Tumors \\> 1 cm, other citological type, refusal of MITT, unsuitable for MITT, unmanageable coagulative disorders\n* Patients with psychiatric, addictive, or any disorder, which compromises ability to give informed consent for participation in this study",{"count":157,"type":20},270,"This is a prospective cohort study to test Minimally Invasive Treatments of the Thyroid (MITT) as potential alternative to surgery in patients with Papillary Thyroid MicroCarcinoma (PTMC)",[24],"2024-03-21",{"date":162,"type":31},"2024-03-27",{"date":164,"type":31},"2022-10-10",{"date":166,"type":20},"2035-12-31",{"name":168,"class":38},"European Institute of Oncology"]